Product category:
Contract research
News Release from: Melbourn Scientific
Edited by the Laboratorytalk Editorial
Team on 06 March 2006
Melbourn inspected under Clinical Trials
Directive
Melbourn Scientific is one of first UK labs inspected for good manufacturing practice (GMP) under the EU Clinical Trials Directive
Melbourn Scientific is one of the first analytical laboratories to be inspected for GMP under the EU Clinical Trials Directive, which has made the stringent requirements of good manufacturing practice mandatory for all organisations involved in the manufacture and testing of investigational medicinal products Steve Westcott, managing director of the Melbourn-based pharmaceutical contract laboratories, believes that inspection by MHRA (Medicines and Healthcare products Regulatory Agency) and the feedback it gives to labs will help to drive up safety and quality standards throughout the industry
This article was originally published on Laboratorytalk on 24 Oct 2005 at 8.00am (UK)
Related stories
Clients offered on-line update
Contract research organisation Melbourn Scientific is to launch a unique on-line service offering its global client base up-to-the-minute details on the status of their respective projects.
Pharmacopoeial test facility expanded
It might look like something out of Harry Potter, but it is compulsory for all new products and there are fewer and fewer companies with the specialist skills needed to perform the tests
"These inspections differ from those of the FDA as they focus on the quality control within the laboratory and are not restricted to a single project or product.
"So the investigation was far reaching, ranging from the management of the organisation and training of staff right down to the way that samples are logged and stored.
"The inspectors toured the facility, observing procedures and interviewed staff.
Further reading
Expanded NGI capacity as inhaler testing increases
Pharmaceutical companies are looking to offer improved versions of drugs and new forms of delivery as a method of 'life-cycle management'; inhaled formulations and devices can offer advantages
New drugs challenge dissolution thinking
Less soluble compounds present demanding method development challenges for dissolution testing, and this requires a high degree of expertise when selecting the most appropriate analytical solution
"As such it impacted on everyone and it is a credit to all our staff that we passed with flying colours".
Good manufacturing practice (GMP) ensures that a medicinal product is fit for purpose, ie, it is the right product, right strength, free from contamination and has not deteriorated or degraded in any way - all procedures carried out by an analytical laboratory.
Although many labs were already complying with the intent of the directive, and Melbourn has passed four inspections by the FDA, the MHRA inspection did have some unique features.
As Westcott explains: "With the FDA and other inspections, we are generally asked to comment retrospectively on a procedure.
"The MHRA inspection was much more hands-on.
"In order to demonstrate that its systems and procedures are rigorous, labs are asked to analyse samples from diverse sources using methods that could be new to the analysts involved.
"This is something we do regularly for clients but not before under 'test' conditions, it was like a university practical exam".
For other laboratories facing an inspection Westcott recommends that all staff are briefed about the inspection and all key documentation is made readily available and offers the following reassurance: "A good analytical laboratory will already have the requirements of the directive embedded in its culture and if the inspectors have a good knowledge of the industry then it is an opportunity to gain feedback on best practice in the industry.".
• Melbourn Scientific: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
